Cargando…

Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis

Acute myeloid leukemia (AML) is characterized by arrested differentiation making differentiation therapy a promising treatment strategy. Recent success of inhibitors of mutated isocitrate dehydrogenase (IDH) invigorated interest in differentiation therapy of AML so that several new drugs have been p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomic, Barbara, Smoljo, Tomislav, Lalic, Hrvoje, Dembitz, Vilma, Batinic, Josip, Batinic, Drago, Bedalov, Antonio, Visnjic, Dora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256737/ https://www.ncbi.nlm.nih.gov/pubmed/35790845 http://dx.doi.org/10.1038/s41598-022-15520-z

Ejemplares similares

Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia
por: Smoljo, Tomislav, et al.
Publicado: (2023)

5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts
por: Dembitz, Vilma, et al.
Publicado: (2020)

AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review
por: Višnjić, Dora, et al.
Publicado: (2021)

The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR/Chk1 via pyrimidine depletion
por: Dembitz, Vilma, et al.
Publicado: (2019)

Bendamustine: A review of pharmacology, clinical use and immunological effects
por: Lalic, Hrvoje, et al.
Publicado: (2022)

5-Aminoimidazole-4-carboxamide ribonucleoside-induced autophagy flux during differentiation of monocytic leukemia cells
por: Dembitz, Vilma, et al.
Publicado: (2017)

Properties of Uncommon Indirect Immunofluorescence Staining Patterns Determined during Antinuclear Antibody Detection on HEp-2 Cells
por: Tomić Sremec, Nada, et al.
Publicado: (2021)

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness
por: Barun, Barbara, et al.
Publicado: (2021)

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
por: Xie, Chengzhi, et al.
Publicado: (2013)

Map Task Corpus of Heritage BCMS spoken by second-generation speakers in Switzerland
por: Lemmenmeier-Batinić, Dolores, et al.
Publicado: (2023)

Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis
por: Zhang, Jingyi, et al.
Publicado: (2022)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

The Novel hDHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis
por: Sibille, Giulia, et al.
Publicado: (2022)

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
por: Raut, Lalit S.
Publicado: (2015)

DHODH and cancer: promising prospects to be explored
por: Zhou, Yue, et al.
Publicado: (2021)

The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia
por: Di Tullio, Alessandro, et al.
Publicado: (2017)

HOXA11 plays critical roles in disease progression and response to cytarabine in AML
por: Fu, Jen-Fen, et al.
Publicado: (2021)

Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients
por: Batinić, Josip, et al.
Publicado: (2015)

DHODH tangoing with GPX4 on the ferroptotic stage
por: Wang, Fudi, et al.
Publicado: (2021)

Successful Treatment of Recurrent Gastrointestinal Bleeding Due to Small Intestine Angiodysplasia and Multiple Myeloma with Thalidomide: Two Birds with One Stone
por: Hude, Ida, et al.
Publicado: (2018)

The role of VDR and BIM in potentiation of cytarabine–induced cell death in human AML blasts
por: Harrison, Jonathan S., et al.
Publicado: (2016)

Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
por: Tabe, Yoko, et al.
Publicado: (2018)

Unusual pattern in haemoglobin electrophoresis in Croatian population: a case report
por: Segulja, Dragana, et al.
Publicado: (2016)

The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia
por: Dembitz, Vilma, et al.
Publicado: (2021)

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
por: Gyan, Emmanuel, et al.
Publicado: (2022)

Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach
por: Pugliese, Giusj Monia, et al.
Publicado: (2023)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

DHODH is an independent prognostic marker and potent therapeutic target in neuroblastoma
por: Olsen, Thale Kristin, et al.
Publicado: (2022)

The Warburg effect modulates DHODH role in ferroptosis: a review
por: Amos, Alvan, et al.
Publicado: (2023)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML
por: Schwarer, Anthony P., et al.
Publicado: (2018)

PB1838: TOXICITY AND OUTCOME OF HIGH DOSE CYTARABINE (18 G/M2) FOR AML CONSOLIDATION.
por: Lopes, L., et al.
Publicado: (2022)

DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia
por: Sexauer, Amy N., et al.
Publicado: (2023)

Combination of Cladribine and Cytarabine is Effective for Childhood Acute Myeloid Leukemia: Results of the St. Jude AML97 Trial
por: Rubnitz, Jeffrey E., et al.
Publicado: (2009)

Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients
por: SHIBAYAMA, YOSHIHIKO, et al.
Publicado: (2015)

Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML
por: Bargal, Salma A., et al.
Publicado: (2018)

Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML)
por: Omsland, Maria, et al.
Publicado: (2016)

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
por: Libura, Marta, et al.
Publicado: (2021)

Effect of Granulocyte Colony-Stimulating Factor on the Development of Spermatogenesis in the Adulthood of Juvenile AML Mice Model Treated with Cytarabine
por: Khaleel, Bara’ah, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kstn4k84rtciu4bbhleo57e61l